Antagonism of EG-VEGF Receptors as Targeted Therapy for Choriocarcinoma Progression In Vitro and In Vivo-Reference-Cited by-同舟云学术

Antagonism of EG-VEGF Receptors as Targeted Therapy for Choriocarcinoma Progression In Vitro and In Vivo

Published:2017-09-12 Issue:22 Volume:23 Page:7130-7140
ISSN:1078-0432
Container-title:Clinical Cancer Research
language:en
Short-container-title:Clin Cancer Res

Author:

Traboulsi Wael,Sergent Frédéric,Boufettal Houssine,Brouillet Sophie,Slim Rima,Hoffmann Pascale,Benlahfid Mohammed,Zhou Qun Y.,Balboni Gianfranco,Onnis Valentina,Bolze Pierre A.,Salomon Aude,Sauthier Philippe,Mallet François,Aboussaouira Touria,Feige Jean J.,Benharouga Mohamed,Alfaidy Nadia

Publisher

American Association for Cancer Research (AACR)

Subject

Cancer Research,Oncology

Cited by 32 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Novel Insights into Prokineticin 1 Role in Pregnancy-related Diseases;International Journal of Medical Sciences;2024

2. Impaired decidualization and relative increase of PROK1 expression in the decidua of patients with unexplained recurrent pregnancy loss showing insulin resistance;Journal of Reproductive Immunology;2023-12

3. In Vivo Quantitative Assessment of Gestational Choriocarcinoma Development and Progression Using Luminescent Trophoblast Cells;Methods in Molecular Biology;2023-11-30

4. EG-VEGF maternal levels predict spontaneous preterm birth in the second and third trimesters in pregnant women with risk factors for placenta-mediated complications;Scientific Reports;2023-11-14

5. Effects of Prokineticins on Cerebral Cell Function and Blood–Brain Barrier Permeability;International Journal of Molecular Sciences;2023-10-21